Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency.

Autor: Snodin DJ; Xiphora Biopharma Consulting, Bristol BS6 7BG, U.K., Trejo-Martin A; Gilead Sciences Inc. Nonclinical Safety and Pathobiology (NSP), Foster City, California 94404, United States., Ponting DJ; Lhasa Limited, Granary Wharf House, Leeds, LS11 5PS, U.K., Smith GF; AstraZeneca, Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, Research and Development, CB2 0AA Cambridge, U.K., Czich A; Sanofi, Research and Development, Preclinical Safety, 65926 Frankfurt, Germany., Cross K; Instem, Conshohocken, Pennsylvania 19428, United States., Custer L; Bristol-Myers Squibb, Nonclinical Safety, New Brunswick, New Jersey 08903, United States., Elloway J; AstraZeneca, Safety Sciences, Clinical Pharmacology and Safety Sciences Research and Development, CB2 0AA Cambridge, U.K., Greene N; AstraZeneca, Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, Research and Development, Waltham, Massachusetts 02451, United States., Kalgutkar AS; Medicine Design, Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States., Stalford SA; Lhasa Limited, Granary Wharf House, Leeds, LS11 5PS, U.K., Tennant RE; Lhasa Limited, Granary Wharf House, Leeds, LS11 5PS, U.K., Vock E; Boehringer-Ingelheim Pharma GmbH & Co., KG, 88397 Biberach an der Riss, Germany., Zalewski A; Bayer AG, Pharmaceuticals, Genetic and Computational Toxicology, 13342 Berlin, Germany., Ziegler V; Bayer AG, Pharmaceuticals, Genetic and Computational Toxicology, 13342 Berlin, Germany., Dobo KL; Drug Safety Research and Development, Global Portfolio and Regulatory Strategy, Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States.

Publikováno v: Chemical research in toxicology [Chem Res Toxicol] 2024 Feb 19; Vol. 37 (2), pp. 181-198. Date of Electronic Publication: 2024 Feb 05.

Development of a network of carcinogenicity adverse outcome pathways and its employment as an evidence framework for safety assessment

Autor: Cayley AN; Lhasa Limited, Leeds, West Yorkshire, UK., Foster RS; Lhasa Limited, Leeds, West Yorkshire, UK., Hill E; Lhasa Limited, Leeds, West Yorkshire, UK., Kane S; Lhasa Limited, Leeds, West Yorkshire, UK., Kocks G; Lhasa Limited, Leeds, West Yorkshire, UK., Myden A; Lhasa Limited, Leeds, West Yorkshire, UK., Newman D; Lhasa Limited, Leeds, West Yorkshire, UK., Stalford SA; Lhasa Limited, Leeds, West Yorkshire, UK., Vessey JD; Lhasa Limited, Leeds, West Yorkshire, UK., Zarei R; Lhasa Limited, Leeds, West Yorkshire, UK., De Oliveira AAF; Lhasa Limited, Leeds, West Yorkshire, UK.

Publikováno v: ALTEX [ALTEX] 2023; Vol. 40 (1), pp. 34–52. Date of Electronic Publication: 2022 May 13.

Beyond adverse outcome pathways: making toxicity predictions from event networks, SAR models, data and knowledge.

Autor: Ball T; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Barber CG; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Cayley A; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Chilton ML; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Foster R; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Fowkes A; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Heghes C; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Hill E; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Hill N; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Kane S; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Macmillan DS; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Myden A; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Newman D; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Polit A; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Stalford SA; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Vessey JD; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK.

Publikováno v: Toxicology research [Toxicol Res (Camb)] 2021 Jan 22; Vol. 10 (1), pp. 102-122. Date of Electronic Publication: 2021 Jan 22 (Print Publication: 2021).

The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7.

Autor: Foster RS; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Fowkes A; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Cayley A; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Thresher A; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Werner AD; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Barber CG; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Kocks G; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Tennant RE; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Williams RV; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Kane S; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK., Stalford SA; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS UK.

Publikováno v: Genes and environment : the official journal of the Japanese Environmental Mutagen Society [Genes Environ] 2020 Sep 22; Vol. 42, pp. 27. Date of Electronic Publication: 2020 Sep 22 (Print Publication: 2020).

It's difficult, but important, to make negative predictions.

Autor: Williams RV; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK. Electronic address: richard.williams@lhasalimited.org., Amberg A; Sanofi-Aventis Deutschland GmbH, R&D DSAR/Preclinical Safety FF, Industriepark Hoechst, Bldg. H823, D-65926 Frankfurt am Main, Germany., Brigo A; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070 Basel, Switzerland., Coquin L; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Giddings A; GlaxoSmithKline Pre-Clinical Development, Park Road, Ware, Hertfordshire SG12 0DP, UK., Glowienke S; Novartis Pharma AG, Pre-clinical Safety, Werk Klybeck, CH-4057 Basel, Switzerland., Greene N; Compound Safety Prediction, Pfizer Global Research & Development, 558 Eastern Point Road, Groton, CT 06340, USA., Jolly R; Health/Safety/Environmental, Lilly Research Laboratories, Indianapolis, IN, USA., Kemper R; Vertex Pharmaceuticals Incorporated, 50 Northern Ave, Boston MA, USA., O'Leary-Steele C; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Parenty A; Novartis Pharma AG, Pre-clinical Safety, Werk Klybeck, CH-4057 Basel, Switzerland., Spirkl HP; Sanofi-Aventis Deutschland GmbH, R&D DSAR/Preclinical Safety FF, Industriepark Hoechst, Bldg. H823, D-65926 Frankfurt am Main, Germany., Stalford SA; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Weiner SK; Janssen Research & Development, 1400 McKean Road, Spring House, PA 19477, USA., Wichard J; Bayer Pharma AG, Investigational Toxicology, Muellerstr. 178, S 116, D-13353, Berlin, Germany.

Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2016 Apr; Vol. 76, pp. 79-86. Date of Electronic Publication: 2016 Jan 16.